{"id":11662,"date":"2019-11-04T11:58:37","date_gmt":"2019-11-04T10:58:37","guid":{"rendered":"https:\/\/www.bm-t.de\/v4\/2021\/oncgnostics-expands-business-relations-in-asia\/"},"modified":"2021-02-03T11:20:10","modified_gmt":"2021-02-03T10:20:10","slug":"oncgnostics-expands-business-relations-in-asia","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2019-en\/oncgnostics-expands-business-relations-in-asia\/","title":{"rendered":"oncgnostics expands business relations in Asia"},"content":{"rendered":"

Approval for cervical cancer screening test for the Chinese market expected in early 2020 \/ First contacts in Japan<\/strong><\/h3>\n
Mid\u00addle: Dr Alfred Hansel and Dr Mar\u00adtina Schmitz; oncg\u00adnos\u00adtics GmbH vis\u00adit\u00ading the Chi\u00adnese part\u00adner GeneoDx; (archive image 2018)<\/figcaption><\/figure>\n

The Chi\u00adnese part\u00adner com\u00adpany GeneoDx, a SINOPHARM sub\u00adsidiary, pre\u00adsented the results of its recently com\u00adpleted approval study for the National Med\u00adical Prod\u00aducts Admin\u00adis\u00adtra\u00adtion (NMPA) for the mol\u00ade\u00adc\u00adu\u00adlar bio\u00adlog\u00adi\u00adcal test Gyn\u00adTect to oncg\u00adnos\u00adtics\u2019 man\u00adag\u00ading direc\u00adtors Dr Mar\u00adtina Schmitz and Dr Alfred Hansel in Shang\u00adhai. The approval of Gyn\u00adTect for the Chi\u00adnese mar\u00adket is expected in early 2020. The test allows the reli\u00adable and rapid diag\u00adno\u00adsis of cer\u00advi\u00adcal can\u00adcer (cer\u00advi\u00adcal car\u00adci\u00adnoma) and its precursors.
\n\u201cOur part\u00adners have con\u00adducted a study with around 1,300 sam\u00adples. The results look very promis\u00ading. We are opti\u00admistic that GeneoDx will receive mar\u00adket\u00ading approval for Gyn\u00adTect with\u00adout any prob\u00adlems. In addi\u00adtion, high-level pub\u00adli\u00adca\u00adtions will fol\u00adlow from the study,\u201d says oncg\u00adnos\u00adtics CEO Dr Mar\u00adtina Schmitz.
\nIn Japan, Dr Alfred Hansel vis\u00adited Bio\u00adJapan<\/a> in Yoko\u00adhama from 9 to 11 Octo\u00adber. At the con\u00adfer\u00adence, he cul\u00adti\u00advated exist\u00ading con\u00adtacts that he had made dur\u00ading a visit to MedTech Japan in Tokyo in the spring of this year<\/a>. He also held talks with other com\u00adpa\u00adnies about the mar\u00adket\u00ading oppor\u00adtu\u00adni\u00adties for Gyn\u00adTect in Japan and other coun\u00adtries in the South\u00adeast Asia region.
\nThe Asian mar\u00adket is not only inter\u00adest\u00ading for oncg\u00adnos\u00adtics with regard to Gyn\u00adTect. Inter\u00adna\u00adtional part\u00adner\u00adships are also being sought for the cur\u00adrent pipeline projects, in par\u00adtic\u00adu\u00adlar the devel\u00adop\u00adment of assays in the field of head and neck tumour diagnostics.
\nRoy\u00adalty-free image mate\u00adr\u00adial: www.mynewsdesk.com\/oncgnostics<\/del><\/a> and at www.oncgnostics.com\/downloads<\/a><\/p>\n

About oncgnostics<\/h3>\n

Jena-based oncg\u00adnos\u00adtics GmbH spe\u00adcialises in the early detec\u00adtion of can\u00adcer. Its tests detect changes that are char\u00adac\u00adter\u00adis\u00adtic of the DNA of can\u00adcer cells. The com\u00adpany, founded in 2012, launched Gyn\u00adTect in 2015. In the con\u00adtext of early cer\u00advi\u00adcal can\u00adcer detec\u00adtion, the test clar\u00adi\u00adfies whether cer\u00advi\u00adcal can\u00adcer or pre\u00adcan\u00adcer\u00adous lesions are already present. In April 2017, the two com\u00adpa\u00adnies GeneoDx and oncg\u00adnos\u00adtics signed an exclu\u00adsive licens\u00ading agree\u00adment for Gyn\u00adTect<\/a> in China, Hong Kong and Macao. oncg\u00adnos\u00adtics GmbH is also research\u00ading clar\u00adi\u00adfi\u00adca\u00adtion tests for other types of can\u00adcer. Detailed infor\u00adma\u00adtion is avail\u00adable at www.oncgnostics.com<\/a>.<\/p>\n

About GynTect<\/h3>\n

Gyn\u00adTect is a mol\u00ade\u00adc\u00adu\u00adlar bio\u00adlog\u00adi\u00adcal test that detects six regions of the human genome that are only present in methy\u00adlated form dur\u00ading the devel\u00adop\u00adment of can\u00adcer cells. Thus, Gyn\u00adTect detects patients with malig\u00adnant changes.
\n\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2013<\/p>\n

Contacts<\/h3>\n

oncg\u00adnos\u00adtics GmbH<\/strong>
\nInes Sommer
\nCom\u00admu\u00adni\u00adca\u00adtion and Marketing
\nWinz\u00ader\u00adlaer Str. 2 (Bioin\u00adstru\u00adment Centre)
\n07745 Jena
\nPhone +49 3641 55485\u201300
\nines.sommer@oncgnostics.com<\/a>
\nwww.oncgnostics.com<\/a><\/p>\n

Media Agency
\nTower PR
\nMiriam Mathias
\nM\u00e4lz\u00ader\u00adstrasse 3
\n07745 Jena
\nTel. +49 3641 87611\u201380
\noncgnostics@tower-pr.com
\nwww.tower-pr.com<\/p>\n","protected":false},"excerpt":{"rendered":"

Approval for cer\u00advi\u00adcal can\u00adcer screen\u00ading test for the Chi\u00adnese mar\u00adket expected in early 2020 \/ First con\u00adtacts in Japan The Chi\u00adnese part\u00adner com\u00adpany GeneoDx, a SINOPHARM sub\u00adsidiary, pre\u00adsented the results of its recently com\u00adpleted approval study for the National Med\u00adical Prod\u00aducts Admin\u00adis\u00adtra\u00adtion (NMPA) for the mol\u00ade\u00adc\u00adu\u00adlar bio\u00adlog\u00adi\u00adcal test Gyn\u00adTect to oncg\u00adnos\u00adtics\u2019 man\u00adag\u00ading direc\u00adtors Dr Mar\u00adtina Schmitz [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":6950,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[148],"tags":[202],"class_list":["post-11662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2019-en","tag-press"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=11662"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11662\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/6950"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=11662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=11662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=11662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}